EDUCATIONAL TOOL ONLY. Not legal or medical advice. Not affiliated with the VA.
← All Condition GuidesCLAIM RECON INTEL
Thyroid Cancer
DC 7914 | 38 CFR § 4.119, DC 7914 |
Thyroid Cancer is rated by the U.S. Department of Veterans Affairs under DC 7914 of 38 CFR § 4.119, DC 7914 across 4 severity tiers (100% -- Severe systemic involvement / 60% -- Significant systemic involvement / 30% -- Moderate symptoms requiring continuous medication / 10% -- Mild symptoms or medication-controlled). Service connection requires (1) a current diagnosis, (2) an in-service event, injury, or exposure, and (3) a medical nexus opinion linking the two under 38 C.F.R. § 3.303.
OVERVIEW
Malignant neoplasm of the thyroid gland. Rated 100% during active disease and for 6 months following completion of treatment, then rated on residuals (typically hypothyroidism requiring medication).
RATING CRITERIA (4 LEVELS)
100% -- Severe systemic involvement
Marked involvement of multiple body systems requiring intensive management.
60% -- Significant systemic involvement
Significant complications requiring multiple medications and activity restriction.
30% -- Moderate symptoms requiring continuous medication
Moderate symptoms controlled with continuous medication.
10% -- Mild symptoms or medication-controlled
Mild symptoms or condition controlled with medication alone.
KEY EVIDENCE TO GATHER
-Service treatment records
-Current medical diagnosis and treatment records
-Buddy/lay statements
-Prescription history
-Employment impact documentation
-Any relevant diagnostic testing
C&P EXAM TIPS (5)
1.Bring all relevant medical records and a written list of symptoms.
2.Report your worst days, not your best. The VA rates based on overall impairment.
3.Document how the condition affects daily activities, work, and relationships.
4.Mention all medications and their side effects.
5.Bring buddy statements from people who observe your symptoms.
EDUCATIONAL TOOL ONLY. NOT LEGAL OR MEDICAL ADVICE.
NOT AFFILIATED WITH THE U.S. DEPARTMENT OF VETERANS AFFAIRS.
CLAIM RECON 2026